Little is known about serum vitamin D levels following hematopoietic cell transplantation (HCT). Patients are instructed to avoid sun exposure because of an increased risk of skin cancers. Altered gastrointestinal absorptive capacity as a result of GVHD, bile acid or pancreatic enzyme insufficiency or bacterial overgrowth may lead to difficulty in absorbing the fat-soluble vitamin D. This study was undertaken to determine the prevalence of serum 25-hydroxyvitamin D (25(OH)D) deficiency, and factors associated with 25(OH)D deficiency, among children and adults who were at least 1 year following HCT. A total of 95 participants (54 males and 41 females) completed a questionnaire on usual diet and lifestyle, and provided a blood sample for 25(OH)D determinations between November 2008 and July 2009. The majority of participants had serum 25(OH)D levels X75 nmol/L (n ¼ 62, 65%), 23 had insufficient levels (50-75 nmol/L) and 10 participants were deficient (o50 nmol/L). The majority of participants reported regular use of vitamin D supplements (n ¼ 58, 61%). Prednisone use was significantly inversely associated with serum 25(OH)D concentrations. Total vitamin D intake was the strongest single predictor of 25(OH)D concentrations. These findings suggest that 400-600 IU vitamin D per day appears to be required to achieve optimal serum 25(OH)D concentrations following HCT.
Introduction
Vitamin D, a sterol hormone precursor, is well-known for its role in maintaining calcium homeostasis and normal bone structure. Recent evidence suggests that in addition to calcium homeostasis, the vitamin may also have a role in cancer incidence and recurrence, 1 risk of infectious diseases 2 and modulation of inflammatory pathways. [3] [4] [5] Thus, for cancer survivors treated with hematopoietic cell transplantation (HCT), there is the possibility that maintaining adequate vitamin D status throughout the course of HCT may decrease risk of GVHD, graft rejection, infectious complications and disease relapse, which in turn, could result in improved survival rates compared with individuals who are vitamin D deficient. In fact, several recent studies have reported an association between higher serum 25-hydroxyvitamin D (25(OH)D) levels and improved survival among individuals with colon, 6 breast, 6 prostate 6 and non-small-cell lung cancers, 7 as well as Hodgkin's lymphoma. 6 Vitamin D deficiency has been associated with muscle weakness, 8, 9 musculoskeletal pain 10 and impaired cognition; 11 all issues common among cancer survivors who may contribute to diminished quality of life.
The 25(OH)D metabolite is the primary circulating form of vitamin D, and is considered the more clinically relevant form for assessing overall vitamin D status. A consensus has emerged that a serum 25(OH)D concentration of at least 75 nmol/L (30 ng/mL) is needed to prevent an increase in parathyroid hormone or impaired calcium absorption, 12 but it is unclear whether this level is optimal for prevention of other health-related issues. Season, age, race, sex, obesity and dietary vitamin D intake have been previously reported to influence serum 25(OH)D concentrations in the general population. 13 Vitamin D 3 is available in fortified foods and dietary supplements, and is produced endogenously in the skin upon exposure to UV radiation. Vitamin D 2 is only available exogenously through fortified foods and dietary supplements.
Little is known about serum vitamin D levels after HCT, although there is reason to believe that vitamin D deficiency is common, given reports of high prevalence of vitamin D insufficiency/deficiency in the US population, 14 as well as among cancer survivors [15] [16] [17] [18] and the critically ill. 19 Following HCT, patients are instructed to avoid sun exposure and to use sunscreen because of an increased risk of skin cancers. 20 Use of certain medications, such as glucocorticoids commonly used to treat GVHD, have been associated with lower serum vitamin D levels, [21] [22] [23] although it is unclear whether this is due to the drug itself, or concurrent lack of vitamin D exposure from diet, supplements or UV exposure. Also some individuals develop altered gastrointestinal absorptive capacity following HCT as a result of gastrointestinal GVHD, intestinal bile-salt deficiency, pancreatic enzyme insufficiency or bacterial overgrowth; consequently, these individuals may have difficulty absorbing dietary fat and fat-soluble vitamins such as vitamin D. 24 Osteoporosis is a common complication among long-term HCT survivors, again suggesting that vitamin D deficiency may be present.
The specific aim of this pilot study was to determine the prevalence of 25(OH)D deficiency among long-term (X1 year) cancer survivors who received HCT. We hypothesized that the majority of these individuals would have suboptimal serum vitamin D levels because of avoidance of sun exposure, regular use of sunscreen, suboptimal dietary/ supplemental intake and treatment-related factors.
Materials and methods

Study population
Study participants for this observational study were recruited from patients scheduled for clinic visits in the BMT Clinic, the adult BMT long-term follow-up clinic and the pediatric long-term follow-up clinic at the University of Minnesota between November 2008 and July 2009. Patients were eligible to participate in the study if they were at least 1 year from the date of HCT for any diagnosis, except multiple myeloma. Patients who had undergone HCT for multiple myeloma were excluded from this study because of the potential for alterations in skeletal metabolism and renal function, and the likelihood of concurrent treatment with bisphosphonates and higher doses of vitamin D supplementation. This study was approved by the University of Minnesota Institutional Review Board, and all participants (or their guardians) provided written informed consent.
Data collection
Medical records and the HCT databases were used to abstract diagnostic and treatment-related data for each participant. Data collected included original cancer diagnosis, pretreatment height (adults), current height (children), current weight, date of transplant, HCT conditioning regimen, donor matching status, GVHD prophylaxis regimen, history of acute and chronic GVHD, current medications and comorbidities.
Dietary vitamin D intake was obtained from a selfadministered questionnaire adapted from a validated short screening instrument by Blalock et al. 25 The questionnaire asked participants about usual intake of food sources high in vitamin D (milk, salmon, tuna, eggs and fortified cereals) over the past month. For dietary vitamin D intake, micrograms of vitamin D per serving of milk as a beverage, milk on cereal, salmon, tuna and eggs, were calculated using a 100 g reference value for each food from the United States Department of Agriculture National Nutrient Database for Standard Reference. Recent supplemental vitamin D intake data were collected at the time of the clinic visit. Participants were asked to bring dietary supplements that they were currently taking to the clinic visit. Information on the type and amount of vitamin D provided was collected from the supplement facts label, and the study participant was asked to report frequency of use over the past month. Participants were also asked to report their average number of hours of daily sun exposure on weekdays and on weekend days over the previous month, and frequency of sunscreen use.
For study participants less than 18 years of age at the time of the study, study paperwork, including the questionnaire, was provided to the parents or legal guardians. In most cases, it was the parent who completed the study questionnaire on behalf of their child.
Serum for the 25(OH)D determinations was obtained during the routine blood draw for the participant's clinic visit. Fairview Diagnostic Laboratories (Minneapolis, MN, USA) performed the serum 25(OH)D determinations using liquid chromatography/tandem mass spectrometry methods.
Statistical analysis
For this analysis, serum 25(OH)D deficiency was defined as serum levels o50 nmol/mL (20 ng/mL), insufficiency as 50-74.9 nmol/L, (20-29.9 ng/mL), and sufficient as X75 nmol/L (30 ng/ml). 26 The distribution of serum 25(OH)D concentrations were skewed toward higher values, therefore these values were log-transformed for use in the statistical analyses. Geometric means and 95% confidence intervals are presented, which were obtained by taking the anti-log of the mean and 95% confidence intervals. We evaluated whether seasonal variation in serum 25(OH)D concentrations was present in this cohort by comparing mean 25(OH)D concentrations by month and season (March-May, June-August, SeptemberNovember and December-February) of blood draw.
Descriptive statistics, including geometric means, s.d., frequencies and ranges, were obtained for the entire cohort and stratified by age group at the time of the blood draw: children/adolescents (o20-years old), young adults (20-40 years old) and adults (440-years old). Where sufficient numbers were present, analyses were also stratified on key covariates such as sex, years since transplant (1-1.9, 2-4.9, X5), type of transplant (autologous vs allogeneic), conditioning regimen (myeloablative vs non-myeloablative), history of acute-and chronic GVHD, use of immunosuppressive medications (yes/no) and use of vitamin D supplement (yes/no). Analyses were also stratified by body weight category according to the BMI-for-age for children and adolescents less than 20 years of age 27 and BMI for adults. Body weight was categorized as: underweight (o5th percentile BMI-for-age or BMI o18.5), normal weight (5th-84th percentile BMI-for-age or BMI 18.5-24.9), overweight (85th-94th percentile BMI-for-age or BMI 25.0-29.9) and obesity (X95th percentile BMI-for-age or BMI X30).
Multivariable linear regression was used to model the predictors of 25(OH)D concentration. Current age (continuous), sex, month of blood draw, BMI or BMI-for-age percentile (continuous), self-reported race (white/other), self-reported average daily hours of sun exposure, usual dietary vitamin D intake, usual supplemental vitamin D intake, clinical serum chemistry concentrations at the same blood draw (calcium, creatinine, albumin, ALT, AST and alkaline phosphatase), type of HCT (allogeneic/autologous), conditioning regimen (myeloablative/non-myeloablative), history of acute and chronic GVHD, and current use of immunosuppressants (yes/no) and prednisone (yes/ no) were considered as potential predictors. Each potential predictor was examined individually by assessing its effect on the overall model fit (R 2 , F-test). Statistical significance for all analyses was defined as a P-value of o0.05. Statistical analyses were performed using SAS 9.1 data analysis software (SAS Institute Inc., Cary, NC, USA).
Results
A total of 95 long-term HCT survivors (44 children/ adolescents, 12 young adults and 39 adults), out of a total of 170 (56%) potentially eligible individuals, agreed to participate in this study. Non-participation most commonly occurred through passive refusal (no response to study mailings or telephone contact by the study coordinator before the scheduled clinic visit); only five individuals actively declined participation. Nonparticipants did not differ from participants by sex, time since HCT or original diagnosis (P40.05), however, nonparticipants tended to be younger than participants (mean: 21.8 vs 31.7 years, respectively, Po0.01). The characteristics of the study population are described in Table 1 . Slightly more than half the participants were male and the majority (87%) were Caucasian. Most study participants resided in northern US states at the time of the study (Minnesota, Wisconsin, North and South Dakota, Michigan, Iowa, Illinois, New Jersey and Rhode Island), although four (4%) of study participants resided in southern US states (Florida, Georgia and California).
Overall, more than half of the participants were using vitamin D supplements. However, a significantly higher percentage of young adults and adults used supplements compared with children/adolescents (78 vs 41%, Po0.01). Likewise, mean supplemental vitamin D intake was statistically significantly higher among young adults and adults than among children (mean: 259 vs 85 IU/day, Po0.01). Mean dietary vitamin D intake was 144 IU per day, and was not statistically significantly different across age groups.
No statistically significant differences in mean 25(OH)D by month or season of blood draw were observed in this cohort. Mean self-reported hours of sun exposure was 1.1 h per day for the entire cohort, with no statistically significant differences by age group. The majority of participants reported rarely or never using sunscreen, although a greater percentage of young adults (50%) reported always using sunscreen compared with the percentages of children/ adolescents (16%) or adults (21%). No statistically significant differences in average daily sun exposure by sunscreen use category was observed, even when stratified by age category (data not shown).
Contrary to our original hypothesis, the majority of study participants had sufficient serum 25 Stratification by transplant and patient characteristics (Table 2) indicates that type of transplant (autologous or allogeneic) was not associated with significant differences in serum 25(OH)D concentrations. Adults who received non-myeloablative conditioning regimens had significantly higher serum 25(OH)D concentrations than adults who underwent myeloablative regimens (P ¼ 0.01). Conditioning regimen was not associated with significant differences in serum 25(OH)D concentrations among children/adolescents. History of acute or chronic GVHD was not associated with significant differences in serum 25(OH)D concentrations.
As has been commonly reported, [28] [29] [30] Vitamin D status after HCT K Robien et al Table 2 Effect According to Centers for Disease Control categorizations using sex-specific BMI-for-age for children and adolescents (2-19 years of age), and BMI for adults.
Vitamin D status after HCT K Robien et al
Discussion
In this cohort of long-term HCT survivors, the majority (64%) of study participants had sufficient vitamin D levels, likely as a result of vitamin D supplement use, which was highly prevalent in the study population. Total dietary and supplemental vitamin D intake was the strongest single predictor of 25(OH)D concentrations, and 400-600 IU per day appear to be required to achieve optimal serum 25(OH)D concentrations across 95% of the study population. The lack of seasonal variation in 25(OH)D concentrations suggests that study participants were generally adhering to recommendations to minimize UV exposure following HCT. Prednisone use was significantly inversely associated with serum 25(OH)D concentrations. Although the inverse association between prednisone use and serum 25(OH)D concentrations may indicate a direct effect of prednisone on either vitamin D absorption or metabolism, the prednisone use variable may also be acting a surrogate for an individual's heightened awareness of the need to limit UV exposure, or decreased appetite limiting dietary and supplemental vitamin D intake. In our study, no statistically significant differences in dietary vitamin D intake, supplemental vitamin D intake or average hours of sun exposure were observed between those who were currently taking prednisone and those who were not. Participants on prednisone were likely receiving the medication because of active chronic GVHD, and vitamin D absorptive capacity may have been reduced among those with gastrointestinal GVHD. We did not collect data on prednisone dose; future studies are needed to determine whether a dose-effect relationship exists between prednisone and vitamin D status.
To our knowledge, this is the first study to report vitamin D status among long-term survivors following HCT. A small study of 48 patients undergoing allogenic HCT found that 25(OH)D declined significantly from pretreatment levels to time of engraftment (approximately 1 month after transplant). 31 Before HCT, mean serum In this study, 400-600 IU dietary or supplemental vitamin D per day appears to be required to achieve optimal serum 25(OH)D concentrations across 95% of the study population after adjusting for prednisone use. The current Dietary Recommended Intakes for adequate intake of vitamin D among healthy individuals is 200 IU per day for individuals up to 50 years of age, 400 IU per day for individuals aged 51-70 years and 600 IU per day for those 71 and older. 32 Thus, our findings suggest that following HCT, vitamin D requirements may be higher than the current recommendations. However, the Institute of Medicine has convened an expert panel to reevaluate the current Dietary Recommended Intakes for calcium and vitamin D, and the adequate intake recommendations are expected to increase when the committee releases their report, which is expected to be made publically available in November 2010. 33 Our study had several strengths and limitations. One strength is that this is the first study to consider dietary and supplemental vitamin D intake, as well as UV exposures, as potential predictors of vitamin D status among patients with a history of HCT. Despite our relatively large study population, we did not have sufficient numbers to fully evaluate the effect of potential confounding factors for differences by age group. We were also limited in having only one measurement of vitamin D status, which may not have been reflective of long-term vitamin D status. Another limitation is that there is considerable heterogeneity in overall health status and health issues among patients who have undergone HCT, and healthier patients (who might be more likely to be vitamin D sufficient) may have been more likely to participate in the study. A larger study population would have allowed for restriction to specific sub-populations (for example, specific underlying diagnoses, treatment regimens, comorbid conditions, time since transplant and so on) to isolate these factors with regard to effect on vitamin D status. We also lacked sufficient numbers to fully explore potential effects of medications on vitamin D status.
Further prospective studies are needed to confirm our findings related to specific adequate vitamin D intake 
